Endologix Inc. announced that it has received Investigational Device Exemption (IDE) conditional approval from the United States Food and Drug Administration to begin a prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR) utilizing the Company's IntuiTrak(TM) endovascular delivery system for the Powerlink® family of stent grafts. Standard EVAR procedures require an open surgical cut-down of one or both femoral arteries for delivery system access and device deployment. Percutaneous EVAR (PEVAR) procedures do not require an open surgical cut-down of either femoral artery, as access to the femoral artery is achieved via a percutaneous ('across the skin') approach. There are currently no medical devices approved by the FDA, or in pivotal clinical trials, for a percutaneous EVAR indication. The Company plans to initiate this first pivotal clinical trial for percutaneous EVAR in the first quarter of 2010. Based on the trial results, Endologix intends to submit a future PMA supplement for a broadened indication for the IntuiTrak endovascular delivery system to include PEVAR in suitable patients and will initiate widespread physician training programs on this technique. The trial will utilize a 'pre-close' technique facilitated by the Prostar® XL Percutaneous Vascular Surgical System or Perclose ProGlide® Suture-Mediated Closure System, both made by Abbott. Up to 20 U.S. clinical sites will enroll 150 patients in the randomized trial. One hundred patients will undergo PEVAR with closure facilitated by either the Prostar XL or Perclose ProGlide device, and 50 patients will undergo standard surgical cut-down EVAR. All patients will be treated with the IntuiTrak endovascular delivery system.

Endologix Inc. - Conference Presentation Calls

On October 30, 2009, Endologix Inc. entered into a credit agreement with Wells Fargo Bank, National Association, whereby Wells Fargo made available to Endologix a secured credit facility in the form of a revolving line of credit up to a maximum of $10.0 million. Endologix may use borrowings under the Facility for general working capital and corporate purposes. All outstanding amounts under the Facility bear interest at a variable rate equal to the greater of 90-day LIBOR, the federal funds rate, or Wells Fargo’s prime rate, plus 1.25%, which is payable on a monthly basis. The unused portion of the Facility is subject to an unused revolving line facility fee, payable quarterly, in arrears, on a calendar year basis, in an amount equal to 0.2% per annum of the average unused portion of the facility, as determined by Wells Fargo. The facility also contains customary covenants regarding operations of Endologix business and financial covenants relating to ratios of current assets to current liabilities and tangible net worth. The Facility is secured by a security interest granted to Wells Fargo in all of the property of Endologix other than its intellectual property. All amounts owing under the Facility will become due and payable on April 30, 2012.